



TETRATHERIX LISTS ON ASX FOLLOWING SUCCESSFUL IPO

- Tetratherix lists on ASX following successful IPO comprised of \$25m raising at \$2.88 per share, with a market capitalisation of \$145m at listing and an enterprise value of approximately \$113m (~\$6m cash at bank at time of Prospectus)
- Tetratherix develops novel clinical products based on its patented biomaterial polymer platform technology – Tetramatrix™
- The unique platform biomaterial, protected by +35 granted patents, underpins long-term pipeline
- Bone Regeneration products with clear pathway towards commercialisation
- Partnership model leverages partners' best-in-class infrastructure
- Regulatory approval process well defined through regulator engagements and strategic partnerships
- Highly experienced management and technical team, supported by tier 1 scientific advisors and board
- Supportive existing shareholder base which includes Rod Drury's Radar Ventures, Ryder Innovation Fund, Possible Ventures Terasaki Institute for Biomedical Innovation.
- Strong alignment with Board and Management owning 38%, highlighted by Chair Emma Cleary investing at the IPO
- Tetratherix will host an investor webinar tomorrow, Tuesday 1 July at 11.30am AEST to provide an overview of the Company and discuss recent achievements. [Click here to register.](#)

Tetratherix Limited (ASX:TTX) ("Tetratherix" or the "Company"), an Australian medical technology company pioneering advanced biomaterial solutions to transform how complex diseases are treated, is pleased to announce the official listing of its shares on the Australian Securities Exchange (ASX) after raising \$25m in an initial public offering (IPO) which marks a major milestone in its evolution and future growth trajectory.

The listing represents the beginning of a new chapter for Tetratherix as it transitions to a publicly listed company with a clear purpose: to accelerate the development and commercialisation of its proprietary polymer platform to improve patient outcomes across a wide range of clinical indications.

The Company's platform technology – Tetramatrix™ – is the world's first biostealth fluid matrix and is being used to develop clinical products applicable across numerous areas including bone regeneration, tissue spacing and tissue healing. These markets alone provide the Company with a total addressable market opportunity of a combined US\$6.8 billion.

The Tetramatrix™ material is an injectable fluid that upon administration forms a 3D matrix that physically integrates and adheres to the target tissue. It is modular in nature, possesses similar properties to natural tissue and gradually bioresorbs in the body once it has served its purpose.

Other benefits of Tetramatrix™ include its minimally invasive delivery, low cost, scalable production and the ability to seamlessly integrate it into existing workflows. Another advantage is its medical device classification for regulatory approval processes, enabling a fast track to approval compared with drugs or therapeutic candidates.



The Company anticipates having its first two products in the market in H1 2026, in addition to a commercial pathway that would allow FDA clearance of three additional products over the next four years. This is further backed by a long-term product pipeline out to more than ten years for other clinical use cases, with several of these already in development.

Tetratherix extends its sincere thanks to its long-standing shareholders for their continued support and welcomes its new investors who have joined the Company on this journey. From inception, Tetratherix has been guided by a strong belief in the potential of its materials science platform to address real-world clinical needs.

The offer was comprised of \$25m of primary capital through the issue of 8,680,000 new shares at \$2.88. The IPO values Tetratherix at \$145m. There was no sell down as part of the IPO. Barrenjoey Markets Pty Ltd and Morgans Financial Limited were Joint Lead Managers to the IPO.

Tetratherix CEO Will Knox said: “An ASX listing has long been a goal on our journey as a business, and our near term growth trajectory and commercial momentum make this the right time. On behalf of our leadership team, we would like express our gratitude to all of our staff, investors and partners who have all played a role in helping us reach this exciting milestone.

“This IPO is not an endpoint or an exit strategy, rather a foundation upon which we will will accelerate product development, expand our global clinical footprint and scale manufacturing & commercial operations.”

Investor Webinar

The Company will host a webinar tomorrow, Tuesday 1 July 2025 at 11.30am AEST to provide an overview of the Company as well as further discuss the BioOptix strategic agreement. Co-Founder and CTO Ali Fathi and CEO, Will Knox will present.

Investors will be able to submit questions via the Q&A function in Zoom or alternatively submit question prior to matt@nwrcommunications.com.au.

To register for the webinar, please follow this link:

https://us02web.zoom.us/webinar/register/WN_Gbagjjk1Qs6i1GOszzi3aQ

About Tetratherix

Tetratherix is an Australian medical technology company pioneering advanced biomaterial solutions to transform how complex diseases are treated. Our proprietary polymer platform enables the targeted delivery of cells, drugs, and biologics, unlocking new potential across oncology, regenerative medicine, and more. With a mission to treat as many patients as possible, Tetratherix combines deep scientific innovation with real-world clinical impact—underpinned by a novel business model designed for global scalability and embedded collaboration with partners & healthcare systems around the world.



Capital Structure

Securities on issue

Ordinary shares	27,110,055
Ordinary shares on conversion of preference shares	9,480,550
Total (on issue)	36,590,605

Securities issued

IPO Offer	8,680,000
Ordinary shares on conversion of convertible notes	3,807,270
Ordinary shares on conversion of SAFE Notes.	1,253,762
Total Securities Issued ¹	13,741,032
Grand Total	50,331,637

Note 1: Securities have been issued.

ASX Mandatory Escrow

No of Shares	Restriction Period
23,570,766	Until 30 June 2027, being 24 months from the date of quotation
14,059	Until 2 September 2025, being 12 months from the date of issue
28,117	Until 6 September 2025, being 12 months from the date of issue
101,571	Until 6 December 2025, being 12 months from the date of issue
2,190	Until 20 December 2025, being 12 months from the date of issue
18,951	Until 20 June 2026, being 12 months from the date of issue

Voluntary Escrow

No of Shares	Restriction Period
500,000	Until 3 months from quotation
1,491,740	Until 6 months from quotation
5,950,638	Until 4:15pm on the trading day after the date on which the Company releases to the ASX its financial results for the half year ended December 2025
5,950,629	Until 4:15pm on the trading day after the date on which the Company releases to the ASX its financial results for the half year ended June 2026

< ENDS >

Authorised for release by CEO and CTO

For further information contact:
Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

<https://tetratherix.com/>

